This mechanism could be involved in the reduced COVID-19 mortality observed with sitagliptin, a DDP-4 inhibitor drug used in Type 2 diabetes mellitus, by increasing the soluble form of DPP-4/sCD2642. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.